CURRENT STATUS
Nephrology has broken a decades-long drought: the first disease-specific drugs for rare kidney diseases have arrived and, for the first time, the trajectory toward dialysis can be bent rather than merely watched. Sparsentan (FILSPARI), a dual endothelin/angiotensin receptor antagonist, won full FDA approval for IgA nephropathy and FSGS by lowering proteinuria and preserving eGFR. SGLT2 inhibitors and the non-steroidal mineralocorticoid antagonist finerenone slow diabetic and non-diabetic kidney decline in large outcome trials. Oral complement inhibitors (iptacopan, targeting the alternative pathway) are advancing in IgA nephropathy and C3 glomerulopathy, tolvaptan slows polycystic kidney disease, and deep-learning biopsy reads plus eGFR-slope modeling now separate the many diseases hiding inside "chronic kidney disease." The field has moved from managing decline to targeting mechanism.
KEY BREAKTHROUGHS
Sparsentan (FILSPARI) β first non-immunosuppressive drug fully FDA-approved for IgA nephropathy and FSGS, preserving kidney function
Finerenone (Kerendia) β slows diabetic kidney disease progression and cardiovascular events
SGLT2 inhibitors (dapagliflozin, empagliflozin) β proven to slow CKD progression even without diabetes
Complement inhibitors (e.g., iptacopan) advancing for IgA nephropathy and C3 glomerulopathy
AI-COMPRESSED PIPELINE
AI TOOLS ACCELERATING CURES
KEY ORGANIZATIONS
KEY CLINICAL TRIALS
Iptacopan β Factor B Inhibitor for IgA Nephropathy (APPLAUSE-IgAN, Phase 3)
ViewNovartis
An oral complement Factor B inhibitor that dials down the alternative complement pathway driving IgA nephropathy, aiming to reduce proteinuria and preserve kidney function without broad immunosuppression.
Tolvaptan & Next-Gen Therapies for Polycystic Kidney Disease
ViewOtsuka / academic consortia
Building on tolvaptan (the first drug to slow ADPKD cyst growth), trials are testing RNA- and metabolism-targeted approaches to further slow kidney enlargement and delay dialysis in polycystic kidney disease.
TIMELINE ESTIMATE
Slowing IgA nephropathy, FSGS and diabetic kidney disease: available now. Functional halt of progression: 3β6 years. Regenerative / bioengineered kidneys: 8β15 years.